Volume 10 Supplement 4

Controversies in Breast Cancer 2008

Short communications

Edited by William R Miller, Mitch Dowsett and James N Ingle

Publication of this supplement was supported in part by unrestricted educational grants from AstraZeneca, Novartis, Pfizer and Roche.

Controversies in Breast Cancer 2008.

Edinburgh, UK1-2 September 2008

Controversies in Breast Cancer 2008

Authors: William R Miller

Citation: Breast Cancer Research 2008 10(Suppl 4):S1

Content type: Preface Published on: 18 December 2008
- View Full Text
- View PDF
Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'

Authors: J Michael Dixon and Monica Morrow

Citation: Breast Cancer Research 2008 10(Suppl 4):S2

Content type: Section introduction Published on: 18 December 2008
- View Full Text
- View PDF
Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer

Authors: László Tabar and Peter B Dean

Citation: Breast Cancer Research 2008 10(Suppl 4):S3

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
The utility of conventional and molecular pathology in managing breast cancer

Authors: D Craig Allred

Citation: Breast Cancer Research 2008 10(Suppl 4):S4

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
How much can improved molecular and pathologic discriminants change local therapy?

Authors: Monica Morrow

Citation: Breast Cancer Research 2008 10(Suppl 4):S5

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Introduction to the sessions on 'Debate: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'

Authors: Lesley Fallowfield and David George

Citation: Breast Cancer Research 2008 10(Suppl 4):S6

Content type: Section introduction Published on: 18 December 2008
- View Full Text
- View PDF
Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for

Authors: J Michael Dixon and David A Montgomery

Citation: Breast Cancer Research 2008 10(Suppl 4):S7

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against

Authors: David A Cameron

Citation: Breast Cancer Research 2008 10(Suppl 4):S8

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Introduction to sessions on 'Predicting personal risk for breast cancer'

Authors: Mitch Dowsett

Citation: Breast Cancer Research 2008 10(Suppl 4):S9

Content type: Section introduction Published on: 18 December 2008
- View Full Text
- View PDF
Assessing individual risk for breast cancer: role of oestrogens and androgens

Authors: Richard J Santen

Citation: Breast Cancer Research 2008 10(Suppl 4):S10

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Should lifestyle modifications be promoted to prevent breast cancer?

Authors: Anthony Howell and Michelle Harvie

Citation: Breast Cancer Research 2008 10(Suppl 4):S11

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Identification of personal risk of breast cancer: genetics

Authors: Diana M Eccles

Citation: Breast Cancer Research 2008 10(Suppl 4):S12

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Assessing risk for breast cancer

Authors: Jack Cuzick

Citation: Breast Cancer Research 2008 10(Suppl 4):S13

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Psychosocial aspects of risk appraisal

Authors: Lesley Fallowfield

Citation: Breast Cancer Research 2008 10(Suppl 4):S14

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'

Authors: James N Ingle

Citation: Breast Cancer Research 2008 10(Suppl 4):S15

Content type: Section introduction Published on: 18 December 2008
- View Full Text
- View PDF
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy

Authors: V Craig Jordan, Roshani Patel, Joan S Lewis-Wambi and Ramona F Swaby

Citation: Breast Cancer Research 2008 10(Suppl 4):S16

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer

Authors: James N Ingle

Citation: Breast Cancer Research 2008 10(Suppl 4):S17

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Markers of endocrine sensitivity

Authors: Daniel F Hayes

Citation: Breast Cancer Research 2008 10(Suppl 4):S18

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Identification and mechanisms of endocrine resistance

Authors: William R Miller

Citation: Breast Cancer Research 2008 10(Suppl 4):S19

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Integration of endocrine therapy with targeted agents

Authors: Stephen RD Johnston

Citation: Breast Cancer Research 2008 10(Suppl 4):S20

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Introduction to sessions on 'Optimizing the implementation of future treatments – time to abandon traditional methods'

Authors: Mark Verrill

Citation: Breast Cancer Research 2008 10(Suppl 4):S21

Content type: Section introduction Published on: 18 December 2008
- View Full Text
- View PDF
Strength and weakness of phase I to IV trials, with an emphasis on translational aspects

Although phase I to III trials represent the standard for introducing new drugs to clinical therapy, there has been increasing demand for translational research in oncology over the past decade. Thus, for most...

Authors: Per Eystein Lønning

Citation: Breast Cancer Research 2008 10(Suppl 4):S22

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?

Authors: Kathleen I Pritchard

Citation: Breast Cancer Research 2008 10(Suppl 4):S23

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Neoadjuvant/presurgical treatments

Authors: Ian E Smith

Citation: Breast Cancer Research 2008 10(Suppl 4):S24

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Evaluation of biological agents targeted at early-stage disease

Authors: Marta Guix, Ingrid A Mayer, Ingrid M Meszoely and Carlos L Arteaga

Citation: Breast Cancer Research 2008 10(Suppl 4):S25

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF
Optimizing the implementation of future treatment using surrogate end-points

Authors: Mitch Dowsett

Citation: Breast Cancer Research 2008 10(Suppl 4):S26

Content type: Short communication Published on: 18 December 2008
- View Full Text
- View PDF

Controversies in Breast Cancer 2008

Short communications

Controversies in Breast Cancer 2008

Introduction to sessions on 'What can surgeons do for us (and we for them): radiology, pathology, molecular biology and local therapy'

Thirty years of experience with mammography screening: a new approach to the diagnosis and treatment of breast cancer

The utility of conventional and molecular pathology in managing breast cancer

How much can improved molecular and pathologic discriminants change local therapy?

Introduction to the sessions on 'Debate: Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors'

Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case for

Extended follow-up of breast cancer patients in clinic wastes time for both patients and doctors: the case against

Introduction to sessions on 'Predicting personal risk for breast cancer'

Assessing individual risk for breast cancer: role of oestrogens and androgens

Should lifestyle modifications be promoted to prevent breast cancer?

Identification of personal risk of breast cancer: genetics

Assessing risk for breast cancer

Psychosocial aspects of risk appraisal

Introduction to sessions on 'Endocrine therapy: where have we come from, where are we at and where are we going to?'

By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer

Markers of endocrine sensitivity

Identification and mechanisms of endocrine resistance

Integration of endocrine therapy with targeted agents

Introduction to sessions on 'Optimizing the implementation of future treatments – time to abandon traditional methods'

Strength and weakness of phase I to IV trials, with an emphasis on translational aspects

Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?

Neoadjuvant/presurgical treatments

Evaluation of biological agents targeted at early-stage disease

Optimizing the implementation of future treatment using surrogate end-points

Follow

Annual Journal Metrics

Breast Cancer Research

Contact us